KR20200078497A - 신규의 t-세포 수용체 - Google Patents

신규의 t-세포 수용체 Download PDF

Info

Publication number
KR20200078497A
KR20200078497A KR1020207011102A KR20207011102A KR20200078497A KR 20200078497 A KR20200078497 A KR 20200078497A KR 1020207011102 A KR1020207011102 A KR 1020207011102A KR 20207011102 A KR20207011102 A KR 20207011102A KR 20200078497 A KR20200078497 A KR 20200078497A
Authority
KR
South Korea
Prior art keywords
tcr
cell
cells
cancer
clone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020207011102A
Other languages
English (en)
Korean (ko)
Inventor
앤드류 세웰
게리 돌튼
Original Assignee
유니버시티 칼리지 카디프 컨설턴츠 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 유니버시티 칼리지 카디프 컨설턴츠 리미티드 filed Critical 유니버시티 칼리지 카디프 컨설턴츠 리미티드
Publication of KR20200078497A publication Critical patent/KR20200078497A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020207011102A 2017-10-26 2018-10-22 신규의 t-세포 수용체 Ceased KR20200078497A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1717578.7A GB201717578D0 (en) 2017-10-26 2017-10-26 Novel T-cell receptor
GB1717578.7 2017-10-26
GBGB1806155.6A GB201806155D0 (en) 2017-10-26 2018-04-16 Novel t-cell receptor
GB1806155.6 2018-04-16
PCT/GB2018/053045 WO2019081902A1 (en) 2017-10-26 2018-10-22 NEW LYMPHOCYTE RECEPTOR T

Publications (1)

Publication Number Publication Date
KR20200078497A true KR20200078497A (ko) 2020-07-01

Family

ID=60580240

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207011102A Ceased KR20200078497A (ko) 2017-10-26 2018-10-22 신규의 t-세포 수용체

Country Status (17)

Country Link
US (2) US11725039B2 (https=)
EP (2) EP3700925B8 (https=)
JP (1) JP7289311B2 (https=)
KR (1) KR20200078497A (https=)
CN (1) CN111278855B (https=)
AU (2) AU2018356944A1 (https=)
BR (1) BR112020007880A2 (https=)
CA (1) CA3077635A1 (https=)
DK (1) DK3700925T3 (https=)
EA (1) EA202091015A1 (https=)
ES (1) ES2907819T3 (https=)
GB (2) GB201717578D0 (https=)
IL (1) IL274025A (https=)
MX (1) MX2020004334A (https=)
PL (1) PL3700925T3 (https=)
SG (1) SG11202002537WA (https=)
WO (1) WO2019081902A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023106894A1 (ko) * 2021-12-10 2023-06-15 주식회사 유틸렉스 Mr1 제한적 panck t 세포 및 이의 제조방법

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
AU2021208955A1 (en) * 2020-01-16 2022-07-21 Universität Basel MR1 ligands and pharmaceutical compositions for immunomodulation
US20240016837A1 (en) * 2020-06-10 2024-01-18 Eutilex Co., Ltd. T-cell receptor binding to mr1, and use thereof
JP2023549098A (ja) * 2020-11-04 2023-11-22 フェイト セラピューティクス，インコーポレイティド 固形腫瘍を標的とする多重操作されたｉＰＳＣ及び免疫エフェクター細胞
WO2022118043A1 (en) 2020-12-03 2022-06-09 Enara Bio Limited Novel protein-ligand complex
JPWO2022244876A1 (https=) * 2021-05-20 2022-11-24
WO2022248881A1 (en) 2021-05-28 2022-12-01 Enara Bio Limited Novel protein-ligand complex
CA3225252A1 (en) 2021-07-14 2023-01-19 Jordan JARJOUR Engineered t cell receptors fused to binding domains from antibodies
WO2023002204A1 (en) 2021-07-21 2023-01-26 Enara Bio Limited T-cell receptor
WO2023148494A1 (en) 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
CN119546328A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI775117B (zh) * 2013-08-05 2022-08-21 德商伊瑪提克斯生物科技有限公司 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二）
CN106103711A (zh) * 2013-11-21 2016-11-09 组库创世纪株式会社 T细胞受体和b细胞受体库分析系统及其在治疗和诊断中的应用
WO2018162563A1 (en) * 2017-03-07 2018-09-13 Universität Basel Mr1 restricted t cell receptors for cancer immunotherapy
GB201717578D0 (en) * 2017-10-26 2017-12-13 Univ College Cardiff Consultants Ltd Novel T-cell receptor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023106894A1 (ko) * 2021-12-10 2023-06-15 주식회사 유틸렉스 Mr1 제한적 panck t 세포 및 이의 제조방법

Also Published As

Publication number Publication date
EP3700925A1 (en) 2020-09-02
AU2018356944A1 (en) 2020-04-16
US11725039B2 (en) 2023-08-15
US20210147506A1 (en) 2021-05-20
EP3700925B1 (en) 2021-12-29
JP2021500406A (ja) 2021-01-07
EA202091015A1 (ru) 2020-07-17
CN111278855A (zh) 2020-06-12
WO2019081902A1 (en) 2019-05-02
GB201717578D0 (en) 2017-12-13
CA3077635A1 (en) 2019-05-02
JP7289311B2 (ja) 2023-06-09
DK3700925T3 (en) 2022-04-04
MX2020004334A (es) 2020-08-03
GB201806155D0 (en) 2018-05-30
EP3700925B8 (en) 2022-02-16
US20200369742A1 (en) 2020-11-26
PL3700925T3 (pl) 2022-05-02
BR112020007880A2 (pt) 2020-10-27
CN111278855B (zh) 2024-04-02
IL274025A (en) 2020-06-30
ES2907819T3 (es) 2022-04-26
EP4039700A1 (en) 2022-08-10
AU2024202735A1 (en) 2024-05-30
SG11202002537WA (en) 2020-05-28
US11078252B2 (en) 2021-08-03

Similar Documents

Publication Publication Date Title
CN111278855B (zh) 新的t细胞受体
TWI826891B (zh) 轉染 t 細胞和 t 細胞受體用於癌症免疫治療
CN112236447A (zh) 具有mage-b2特异性的t细胞受体及其用途
JP2017522859A (ja) グリピカン３に特異的なｔ細胞受容体、及び肝細胞癌の免疫療法のためのその使用
CN113195527A (zh) Tcr和肽
CN111826353B (zh) 调节t细胞功能和反应的方法
CN105802909B (zh) 具有her2特异性tcr的t细胞制备物及其用途
CN111372944A (zh) 新型γδT细胞受体和其配体
US20240415886A1 (en) T cell receptor recognizing r175h mutation in p53 and its application
EP3760217A1 (en) Cd5 specific t cell receptor cell or gene therapy
CA3141210A1 (en) Modified nk-92 cells, and therapeutic and diagnostic uses thereof
US20240390423A1 (en) T cell receptor recognizing s37f mutation in ctnnb1 and its application
EA045252B1 (ru) Новый т-клеточный рецептор
US20250064854A1 (en) Novel t-cell receptor
HK40034405B (en) Novel t-cell receptor
HK40034405A (en) Novel t-cell receptor
HK40099489A (zh) 用於癌症免疫治疗的转染t细胞和t细胞受体
Wheeler Identifying a novel γδ T-cell stress ligand: Potential for cancer immunotherapy
HK1257639B (en) Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors
HK1257639A1 (en) Compositions and libraries comprising recombinant t-cell receptors and methods of using recombinant t-cell receptors

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000